Citi initiated coverage of Acadia Pharmaceuticals (ACAD) with a Buy rating and $33 price target The firm believes Nuplazid and Daybue adoption will continue to increase in the near term. Acadia shares are being over-penalized for Nuplazid sales despite the patent litigation being resolved, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Hold Rating Amid Pipeline Shifts and Product Focus
- Acadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche Bank
- ACADIA Pharmaceuticals: Growth Potential Despite Setbacks with Promising Pipeline and Core Business Expansion
- Video: Soleno Therapeutics stock rallies on competitor’s failed trial
- Micron reports Q4 beat, Instagram reports 3B MAUs: Morning Buzz